Table 3.
Impact of lymph node ratio according to different pN stages
|
Characteristic |
|
LRFS |
OS |
||||
|---|---|---|---|---|---|---|---|
| n | 5-year (%) | 10-year (%) | p | 5-year (%) | 10-year (%) | p | |
| pN1 (1–3 positive nodes) |
|
|
|
|
|
|
|
| Lymph node ratio |
|
|
|
|
|
|
|
| < 0.20 |
667 |
90.3 |
88.2 |
0.002* |
87.3 |
79.0 |
0.054 |
| 0.21-0.65 |
107 |
80.0 |
74.8 |
|
80.1 |
71.0 |
|
| > 0.65 |
6 |
83.3 |
— |
|
75.0 |
— |
|
| pN2 (4–9 positive nodes) |
|
|
|
|
|
|
|
| Lymph node ratio |
|
|
|
|
|
|
|
| < 0.20 |
16 |
80.0 |
— |
<0.001* |
84.4 |
56.3 |
0.004* |
| 0.21-0.65 |
141 |
82.1 |
77.2 |
|
72.0 |
55.2 |
|
| > 0.65 |
26 |
44.6 |
— |
|
49.2 |
26.2 |
|
| pN3 (≥ 10 positive nodes) |
|
|
|
|
|
|
|
| Lymph node ratio |
|
|
|
|
|
|
|
| < 0.20 |
7 |
66.7 |
— |
0.508 |
80.0 |
— |
0.013* |
| 0.21-0.65 |
21 |
59.2 |
— |
|
69.3 |
— |
|
| > 0.65 | 77 | 62.2 | 49.8 | 41.4 | 15.4 | ||
LRFS, Locoregional recurrence-free survival; OS, Overall survival.
*p<0.05 indicates a significant difference.